Resources

Press Release

July 17th, 2024

CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts

Blog

May 21st, 2024

Revolutionizing IBD Treatment: The CytoReason and CCF Partnership

Press Release

May 15th, 2024

CytoReason and the Crohn’s & Colitis Foundation Forge Groundbreaking Data Collaboration to Advance IBD Research

Scientific Publications

October 27th, 2023

Reconstructing disease dynamics for mechanistic insights and clinical benefit

Blog

August 22nd, 2023

Navigating Drug Development: CytoReason’s Disease Model Platform

Find out more about the Disease Model Platform by watching our new video

Scientific Publications

June 21st, 2023

Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs

Media Coverage

February 1st, 2023

Making Clinical Trials Better for Everyone in 2023

Media Coverage

January 31st, 2023

Roundtable: What do you view as the most disruptive or transformational technology or development on the horizon?

Media Coverage

January 27th, 2023

Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances

Bring your data to life